Hence, agents that inhibit the Th17 pathway at multiple points, including inhibitors of JAK kinases, IL-23, IL-17A and IL-17RA, are currently being used or evaluated in RA and other autoimmune conditions[9,28]. The gene discussed is IL17A; the disease is rheumatoid arthritis.